Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22730349 | 0.92 | MAPK14 (0.54) | MAPK14GPR119EGFRBRD4 | |
| SCHEMBL22730317 | 0.92 | MAPK14 (0.51) | MAPK14GPR119BRD4 | |
| SCHEMBL7891764 | 0.92 | MAPK14 (0.62) | MAPK14EGFR | |
| SCHEMBL22730528 | 0.90 | MAPK14 (0.52) | MAPK14GPR119EGFRBRD4 | |
| SCHEMBL1640742 | 0.85 | MAPK14 (0.57) | MAPK14GPR119CKS1BSKP1SKP2 | |
| SCHEMBL22730496 | 0.85 | MAPK14 (0.51) | MAPK14GPR119CKS1BSKP1SKP2 | |
| SCHEMBL1639277 | 0.83 | GPR119 (0.50) | MAPK14GPR119CKS1BSKP1SKP2 | |
| SCHEMBL22730461 | 0.81 | BRD4 (0.60) | MAPK14GPR119BRD4 | |
| SCHEMBL22730507 | 0.80 | BRD4 (0.70) | MAPK14BRD4 | |
| SCHEMBL6950452 | 0.80 | MAPK14 (0.71) | MAPK14BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | BRDT, BRD4, BRD3 | MAPK14 2751/4885GPR119 1442/4885CKS1B 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.